Indian Drug Makers Augment HCQ Production Despite Export Ban, an Industrial Info Market Brief

Indian pharmaceutical manufacturers seem to be unmoved by the recent government-imposed ban on the export of the antimalarial drug hydroxychloriquine (HCQs), and continue with their capacity augmentation plans. Many Indian manufacturers, who had discontinued production of the HCQ active ingredient and its formulations due to low demand, have started rebuilding their capacity. This follows a sharp uptick in demand, as the drug is reported to be useful in the treatment of COVID-19.

The Indian government also has banned the export of a host of medical devices, respiratory apparatuses and surgical consumables to ensure their availability in India amid the COVID-19 outbreak. Industrial Info's database includes 811 pharma, biotech and medical devices sector projects. Click here for a list and see map below.